Cargando…

The role of p53 in anti-tumor immunity and response to immunotherapy

p53 is a transcription factor that regulates the expression of genes involved in tumor suppression. p53 mutations mediate tumorigenesis and occur in approximately 50% of human cancers. p53 regulates hundreds of target genes that induce various cell fates including apoptosis, cell cycle arrest, and D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carlsen, Lindsey, Zhang, Shengliang, Tian, Xiaobing, De La Cruz, Arielle, George, Andrew, Arnoff, Taylor E., El-Deiry, Wafik S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Molecular Biosciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434531/ https://www.ncbi.nlm.nih.gov/pubmed/37602328 http://dx.doi.org/10.3389/fmolb.2023.1148389

Ejemplares similares

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
por: Zhang, Shengliang, et al.
Publicado: (2022)

Differential p53-Mediated Cellular Responses to DNA-Damaging Therapeutic Agents
por: Carlsen, Lindsey, et al.
Publicado: (2021)

Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation
por: Carlsen, Lindsey, et al.
Publicado: (2022)

P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9
por: Tian, Xiaobing, et al.
Publicado: (2021)

Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers
por: Carlsen, Lindsey, et al.
Publicado: (2022)

Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells
por: Zhang, Shengliang, et al.
Publicado: (2022)

Editorial: Advances in wild type and mutant p53 research in cancer
por: Hernández-de la Cruz, Olga N., et al.
Publicado: (2022)

Targeting Mutated p53: Naivete and Enthusiasm to Attempt the Impossible
por: El-Deiry, Wafik S.
Publicado: (2023)

Characterization of the Immune Cell Infiltration Landscape of Thyroid Cancer for Improved Immunotherapy
por: Gong, Jing, et al.
Publicado: (2021)

p53 and Zinc: A Malleable Relationship
por: Ha, Jeung-Hoi, et al.
Publicado: (2022)

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
por: Grinkevich, Vera V., et al.
Publicado: (2022)

Opposing effects of BRCA1 mRNA expression on patient survival in breast and colorectal cancer and variations among African American, Asian, and younger patients
por: Leaf, Sofia, et al.
Publicado: (2021)

Pyroptosis-Related Patterns Predict Tumor Immune Landscape and Immunotherapy Response in Bladder Cancer
por: Yan, Yilin, et al.
Publicado: (2022)

Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma
por: Liang, Fangfang, et al.
Publicado: (2021)

Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
por: Ribeiro, Rita, et al.
Publicado: (2022)

Development of Personalized Signature Based on the Immune Landscape to Predict the Prognosis of Osteosarcoma and the Response to Immunotherapy and Targeted Therapy
por: Feng, Xiaofei, et al.
Publicado: (2022)

Construction of a tumor immune infiltration macrophage signature for predicting prognosis and immunotherapy response in liver cancer
por: Huang, Anmin, et al.
Publicado: (2022)

Protein of a thousand faces: The tumor-suppressive and oncogenic responses of p53
por: Marques, Mayra A., et al.
Publicado: (2022)

Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
por: Lin, Xinqing, et al.
Publicado: (2020)

Erratum: Construction of a tumor immune infiltration macrophage signature for predicting prognosis and immunotherapy response in liver cancer
por: Frontiers Production Office,
Publicado: (2022)

The potential interplay between G-quadruplex and p53: their roles in regulation of ferroptosis in cancer
por: Zhang, Lulu, et al.
Publicado: (2022)

Recent findings on the role of wild-type and mutant p53 in cancer development and therapy
por: Babamohamadi, Mehregan, et al.
Publicado: (2022)

Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition
por: Semenov, Oleg, et al.
Publicado: (2022)

Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells
por: Carlsen, Lindsey, et al.
Publicado: (2021)

Anti-schistosomal immunity to core xylose/fucose in N-glycans
por: Prasanphanich, Nina Salinger, et al.
Publicado: (2023)

A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53
por: Hernandez Borrero, Liz, et al.
Publicado: (2021)

Risk Signature Related to Immunotherapy Reaction of Hepatocellular Carcinoma Based on the Immune-Related Genes Associated With CD8(+) T Cell Infiltration
por: Zou, Yiping, et al.
Publicado: (2021)

Cancer-testis antigen CEP55 serves as a prognostic biomarker and is correlated with immune infiltration and immunotherapy efficacy in pan-cancer
por: Xie, Xiaodong, et al.
Publicado: (2023)

P53-Related Anticancer Activities of Drimia calcarata Bulb Extracts Against Lung Cancer
por: Laka, K., et al.
Publicado: (2022)

Nanoparticle-based immunotherapy of pancreatic cancer
por: Noubissi Nzeteu, Gaetan Aime, et al.
Publicado: (2022)

Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
por: Raufi, Alexander G., et al.
Publicado: (2021)

p53–GSDME Elevation: A Path for CDK7 Inhibition to Suppress Breast Cancer Cell Survival
por: Wang, Yueyuan, et al.
Publicado: (2021)

Relevance of Amorphous and Amyloid-Like Aggregates of the p53 Core Domain to Loss of its DNA-Binding Activity
por: Hibino, Emi, et al.
Publicado: (2022)

PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma
por: Paz, Mariana M., et al.
Publicado: (2023)

Mechanotransductive receptor Piezo1 as a promising target in the treatment of fibrosis diseases
por: Xu, Yi, et al.
Publicado: (2023)

The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors
por: Dickinson, Eleanor R., et al.
Publicado: (2015)

The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
por: Hunia, Jaromir, et al.
Publicado: (2022)

The p53 tumor suppressor regulates AKR1B1 expression, a metastasis-promoting gene in breast cancer
por: Di Benedetto, Carolina, et al.
Publicado: (2023)

Construction of m6A-based prognosis signature and prediction for immune and anti-angiogenic response
por: Wang, Xiang-Xu, et al.
Publicado: (2022)

Friend or Foe: Prognostic and Immunotherapy Roles of BTLA in Colorectal Cancer
por: Song, Jingjing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5i65ljq826g1nt7v19kc6tcir4